High Glucose Induces Connective Tissue Growth Factor Expression and Extracellular Matrix Accumulation in Rat Aorta Vascular Smooth Muscle Cells Via Extracellular Signal-Regulated Kinase 1/2.
10.4196/kjpp.2013.17.4.307
- Author:
Yu Mi HA
1
;
Dong Hyup LEE
;
Mina KIM
;
Young Jin KANG
Author Information
1. Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 705-717, Korea. yjkang@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
CTGF;
Diabetic complication;
Extracellular matrix;
Hyperglycemia;
VSMC
- MeSH:
Animals;
Aorta;
Atherosclerosis;
Butadienes;
Cell Proliferation;
Collagen;
Connective Tissue;
Connective Tissue Growth Factor;
Diabetes Complications;
Extracellular Matrix;
Fibronectins;
Fibrosis;
Flavonoids;
Glucose;
Humans;
Hyperglycemia;
Muscle, Smooth, Vascular;
Nitriles;
Phosphotransferases;
Rats;
RNA, Messenger;
RNA, Small Interfering;
Transforming Growth Factor beta
- From:The Korean Journal of Physiology and Pharmacology
2013;17(4):307-314
- CountryRepublic of Korea
- Language:English
-
Abstract:
Connective tissue growth factor (CTGF) is a potent pro-fibrotic factor, which is implicated in fibrosis through extracellular matrix (ECM) induction in diabetic cardiovascular complications. It is an important downstream mediator in the fibrotic action of transforming growth factor beta (TGFbeta) and is potentially induced by hyperglycemia in human vascular smooth muscle cells (VSMCs). Therefore, the goal of this study is to identify the signaling pathways of CTGF effects on ECM accumulation and cell proliferation in VSMCs under hyperglycemia. We found that high glucose stimulated the levels of CTGF mRNA and protein and followed by VSMC proliferation and ECM components accumulation such as collagen type 1, collagen type 3 and fibronectin. By depleting endogenous CTGF we showed that CTGF is indispensable for the cell proliferation and ECM components accumulation in high glucose-stimulated VSMCs. In addition, pretreatment with the MEK1/2 specific inhibitors, PD98059 or U0126 potently inhibited the CTGF production and ECM components accumulation in high glucose-stimulated VSMCs. Furthermore, knockdown with ERK1/2 MAPK siRNA resulted in significantly down regulated of CTGF production, ECM components accumulation and cell proliferation in high glucose-stimulated VSMCs. Finally, ERK1/2 signaling regulated Egr-1 protein expression and treatment with recombinant CTGF reversed the Egr-1 expression in high glucose-induced VSMCs. It is conceivable that ERK1/2 MAPK signaling pathway plays an important role in regulating CTGF expression and suggests that blockade of CTGF through ERK1/2 MAPK signaling may be beneficial for therapeutic target of diabetic cardiovascular complication such as atherosclerosis.
